Markets
2024 Los Angeles Comic-Con
An Incredible Hulk figure display is seen during 2024 Los Angeles Comic-Con (Paul Butterfield/WireImage)

This earnings season isn’t about corporate results. It’s about tariffs.

Implied correlations are climbing into the reporting period, a signal that macro fears outweigh any company-specific nuances.

Luke Kawa

On the eve of JPMorgan’s earnings release, the unofficial kickoff to earnings season, one of the most tried-and-true stock market rules for the reporting period has been completely torn asunder by the trade war.

Typically, the implied correlation of S&P 500 stocks over the next month — that is, how much the members of the index are priced to move independently or in unison — tumbles as we approach the start of earnings.

The reasoning here is simple: different things matter for different companies. So, during a time when we’re getting a lot of company-specific news, stocks are expected to march to the beat of their own drummers.

It’s tough to do that this earnings season because everyone and their mother is squarely focused on one common factor: how much do tariffs change a company’s outlook. So far, a common answer is to say, “I’m not sure.” That’s what Walmart did in pulling its Q1 operating income guidance, what Delta Air Lines’s management said when yanking its full-year outlook, and what CarMax signaled in removing time frames for its financial goals.

The result is that implied correlations are doing the opposite of what they usually do in this window. The chart below shows the one-month change in S&P 500 implied correlations, with vertical lines marking days when JPMorgan reports. The market is saying that macro fears mean we can’t be too nuanced about how individual companies are doing.

As the old adage goes, in a crisis, all correlations go to one. And a recession, for both markets and humans, is a crisis, because as much as you might hate to hear it, the stock market is the economy. There’s a strong correlation between crescendoes in fear about the economy, as judged by mentions of “recession” in news articles, and the one-month implied correlation for the S&P 500.

IMPCORR
Source: Sherwood News

That being said, traders are somewhat expecting a reduction in the intensity of the high-volume, everyone-in-or-out-of-the-pool environment we’ve been in during earnings season. That is to say, implied correlations are running below what the strong trading relationship between members of the S&P 500 has been over the past month.

More Markets

See all Markets

Bulls pour into Joby and Archer options as Trump's push for record defense budget boosts eVTOL names

Options traders appear bullish on electric aircraft makers like Archer Aviation and Joby Aviation on Thursday, with large volumes boosting the stocks following President Trump’s call for a record $1.5 trillion US military budget for 2027.

Both companies, as well as newly public rival Beta Technologies, have sizable defense contracts. In July, Archer CEO Adam Goldstein told Sherwood News that he believes the company’s defense side will outpace its civil air taxi service for at least a decade.

Traders seem to believe him. As of 10:53 a.m. ET, about 31,000 Archer call options had exchanged hands, around 9,000 short of its 20-day average for a full day. Joby saw roughly 20,000 call options traded by the same time, eclipsing its 20-day average. For the most actively traded calls for Joby and Archer (C$17s expiring February 20 and C$9s expiring on Friday, respectively), volumes on the ask side are outstripping the bid or mid, indicating motivated buyers.

markets

Insurers rise as House tees up ACA extension vote

Several health insurers rallied on Thursday as the House of Representatives is expected to pass a measure extending the Affordable Care Act tax credits that expired at the end of 2025.

The scheduled vote comes after a group moderate Republicans broke with leadership to revive the bill, as rising health premiums create a political liability for lawmakers up for election in the midterms this year. While it’s expected to pass the House with support from those Republicans, it faces an uphill battle in the Senate.

The biggest providers of ACA Marketplace plans, like Oscar Health, Molina Healthcare, Centene and UnitedHealthcare, rose on the news.

The ACA tax credits, which subsidize health insurance plans provided by private insurers, were part of a 2021 COVID-19 relief package passed by a Democrat-controlled Congress. The credits expired at the end of 2025, and health premiums are expected to skyrocket as insurers adjust for rising costs of care.

markets

Bloom Energy surges on fuel cell deal with utility

Fuel cell maker and momentum stock favorite Bloom Energy ripped early Thursday, after American Electric Power said one of its subsidiaries would exercise an option — from a previous agreement — to buy additional Bloom products for a fuel cell power plant in an agreement worth $2.65 billion.

AEP also said it had signed a “20-year deal with an unnamed customer to supply the entire output from the fuel cell generation facility that will be located near Cheyenne, Wyoming.”

Analysts at Evercore ISI wrote:

“We view this as a meaningful positive for Bloom as it sheds light on the demand for its product and provides investors insight into the fact that the AEP contract will result in volumes well above the minimum commitment, which had previously been rather opaque.

Additionally, this should also provide confidence in Bloom’s customer diversification as many had typically tethered the company directly to Oracle, given the company’s announced collaboration with the company in July 2025.”

With Thursday morning’s surge, Bloom Energy is up more than 400% over the last 12 months, in a rally driven by investor excitement about surging power demand related to AI data centers. While the company has been profitable — on an adjusted basis — over its last four quarters, it’s also highly valued, with a price-to-forward earnings multiple of more than 100x.

Analysts at Evercore ISI wrote:

“We view this as a meaningful positive for Bloom as it sheds light on the demand for its product and provides investors insight into the fact that the AEP contract will result in volumes well above the minimum commitment, which had previously been rather opaque.

Additionally, this should also provide confidence in Bloom’s customer diversification as many had typically tethered the company directly to Oracle, given the company’s announced collaboration with the company in July 2025.”

With Thursday morning’s surge, Bloom Energy is up more than 400% over the last 12 months, in a rally driven by investor excitement about surging power demand related to AI data centers. While the company has been profitable — on an adjusted basis — over its last four quarters, it’s also highly valued, with a price-to-forward earnings multiple of more than 100x.

markets

Opendoor soars as management says Trump’s push to end institutional home-buying wouldn’t hurt the company

Opendoor Technologies is soaring on Thursday after executives argued that its swoon on Wednesday was an overreaction and misinterpretation by markets.

The online real estate company’s losses deepened yesterday after US President Donald Trump called on Congress to ban institutional investors from buying single-family homes.

Opendoor is a home-flipper rather than a longer-term holder that buys to rent (à la Invitation Homes or American Homes 4 Rent), and if anything, has been aiming to keep homes on its balance sheet for as short a time as possible under new CEO Kaz Nejatian.

Shares were down as much as 13% on Wednesday, but bounced off those lows around 2:15 p.m. ET after Nejatian took to X to endorse the proposal, and are continuing to pare some of those losses today.

Nejatian added, “We’re not institutional investors, our job is to help people buy homes. We don’t hold the homes!”

Chairman Keith Rabois, for his part, said this policy would only have a positive impact on the company, adding that it could increase conversion.

markets

AbbVie says it’s not in talks to buy Revolution Medicines; WSJ reports another suitor may prevail

AbbVie says it “is not in discussions” to acquire oncology biotech Revolution Medicines, bucking previous reporting by The Wall Street Journal and sending both stocks slipping in early trading.

The Journal reported Wednesday that the drugmaker was in advanced talks to acquire Revolution, a company worth about $16 billion before the story published. In a statement to several outlets, AbbVie said it is not in talks to acquire the biotech.

After Abbvie’s statement, the Journal stuck with a lead that the companies were near a deal, “granted the talks don’t hit any last-minute snags.” It also reported that “a deal hasn’t been finalized and another suitor may prevail.”

Revolution soared around 30% on Wednesday. It fell back about 7% Thursday morning.

The acquisition would’ve been the first multibillion-dollar biotech deal of the year, as M&A activity in the sector is heating up. Big Pharma faces a patent cliff in the next few years and is looking for new products to bolster its pipelines, with weight-loss medications and oncology being among the most lucrative.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.